Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioXcel Therapeutics (BTAI) Treasury Shares (2022 - 2025)

BioXcel Therapeutics (BTAI) has 4 years of Treasury Shares data on record, last reported at $139.0 in Q2 2025.

  • For Q2 2025, Treasury Shares fell 99.97% year-over-year to $139.0; the TTM value through Jun 2025 reached $139.0, down 99.97%, while the annual FY2024 figure was $1166.0, 5.97% down from the prior year.
  • Treasury Shares reached $139.0 in Q2 2025 per BTAI's latest filing, down from $140.0 in the prior quarter.
  • Across five years, Treasury Shares topped out at $429000.0 in Q2 2024 and bottomed at $139.0 in Q2 2025.
  • Average Treasury Shares over 4 years is $85027.7, with a median of $1240.0 recorded in 2023.
  • Peak YoY movement for Treasury Shares: skyrocketed 190566.67% in 2024, then tumbled 99.97% in 2025.
  • A 4-year view of Treasury Shares shows it stood at $119000.0 in 2022, then tumbled by 98.96% to $1240.0 in 2023, then fell by 5.97% to $1166.0 in 2024, then crashed by 88.08% to $139.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Treasury Shares were $139.0 in Q2 2025, $140.0 in Q1 2025, and $1166.0 in Q4 2024.